X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. Anhydrous, Potassium Citrate
2. Citrate, Potassium
3. Potassium Citrate Anhydrous
1. Tripotassium Citrate
2. 866-84-2
3. Kaliksir
4. 7778-49-6
5. Potassium Citrate Anhydrous
6. Litocit
7. Potassiumcitrate
8. Citric Acid, Tripotassium Salt
9. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Tripotassium Salt
10. Potassium Citrate Tribasic Solution
11. Tripotassium;2-hydroxypropane-1,2,3-tricarboxylate
12. 86r1nvr0hw
13. Chebi:64733
14. Tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
15. Kalii Citras
16. Porekal
17. Kajos
18. Polycitra K
19. Urocit K
20. Seltz-k
21. K Citrate
22. Potassium Tribasic Citrate
23. Ins No.332(ii)
24. Ins-332(ii)
25. Tripotassium Citrate Anhydrous
26. Acalka
27. Ccris 6566
28. E-332(ii)
29. Hsdb 1248
30. Nsc-760107
31. Einecs 212-755-5
32. Unii-86r1nvr0hw
33. Potassium Citrate (anhydrous)
34. Einecs 231-905-0
35. Tri Potassium Citrate
36. Potassium Citrate (anh.)
37. Anhydrous Potassium Citrate
38. Ec 212-755-5
39. Tripotassium Citrate (anh.)
40. Anhydrous Tripotassium Citrate
41. Potassium Citrate [mi]
42. Chembl1200458
43. Dtxsid8027325
44. Tripotassium Citrate (anhydrous)
45. Potassium Citrate [who-dd]
46. Citric Acid Tripotassium Salt (anh.)
47. Akos015918285
48. Db09125
49. Citric Acid Tripotassium Salt (anhydrous)
50. E332
51. Potassium Citrate Anhydrous [hsdb]
52. Potassium Citrate Anhydrous [mart.]
53. Ft-0653076
54. Potassium 2-hydroxypropane-1,2,3-tricarboxylate
55. A841790
56. Q419921
57. Tripotassium 2-oxidanylpropane-1,2,3-tricarboxylate
58. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Potassium Salt (1:?)
59. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Potassium Salt (1:3)
| Molecular Weight | 306.39 g/mol |
|---|---|
| Molecular Formula | C6H5K3O7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 305.8946469 g/mol |
| Monoisotopic Mass | 305.8946469 g/mol |
| Topological Polar Surface Area | 141 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 211 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
| 1 of 4 | |
|---|---|
| Drug Name | Potassium citrate |
| PubMed Health | Potassium Citrate (By mouth) |
| Drug Classes | Potassium Supplement, Urinary Alkalinizer, Urinary Stone Agent |
| Drug Label | Potassium citrate USP is a citrate salt of potassium and has the chemical name 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate. Its molecular formula is K3C6H 5O7.H2O , and its structural formula is: M.W. 324.41Potassium c... |
| Active Ingredient | Potassium citrate |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 5meq; 15meq; 10meq |
| Market Status | Prescription |
| Company | Corepharma; Zydus Pharms Usa |
| 2 of 4 | |
|---|---|
| Drug Name | Urocit-k |
| PubMed Health | Potassium Citrate (By mouth) |
| Drug Classes | Potassium Supplement, Urinary Alkalinizer, Urinary Stone Agent |
| Drug Label | Urocit-K is a citrate salt of potassium. Its empirical formula is K3C6H5O7 H2O, and it has the following chemical structure:Urocit-K yellowish to tan, oral wax-matrix tablets, contain 5 mEq (540 mg) potassium citrate, 10 mEq (1080 mg) potassi... |
| Active Ingredient | Potassium citrate |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 5meq; 15meq; 10meq |
| Market Status | Prescription |
| Company | Mission Pharma |
| 3 of 4 | |
|---|---|
| Drug Name | Potassium citrate |
| PubMed Health | Potassium Citrate (By mouth) |
| Drug Classes | Potassium Supplement, Urinary Alkalinizer, Urinary Stone Agent |
| Drug Label | Potassium citrate USP is a citrate salt of potassium and has the chemical name 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate. Its molecular formula is K3C6H 5O7.H2O , and its structural formula is: M.W. 324.41Potassium c... |
| Active Ingredient | Potassium citrate |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 5meq; 15meq; 10meq |
| Market Status | Prescription |
| Company | Corepharma; Zydus Pharms Usa |
| 4 of 4 | |
|---|---|
| Drug Name | Urocit-k |
| PubMed Health | Potassium Citrate (By mouth) |
| Drug Classes | Potassium Supplement, Urinary Alkalinizer, Urinary Stone Agent |
| Drug Label | Urocit-K is a citrate salt of potassium. Its empirical formula is K3C6H5O7 H2O, and it has the following chemical structure:Urocit-K yellowish to tan, oral wax-matrix tablets, contain 5 mEq (540 mg) potassium citrate, 10 mEq (1080 mg) potassi... |
| Active Ingredient | Potassium citrate |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 5meq; 15meq; 10meq |
| Market Status | Prescription |
| Company | Mission Pharma |
Diuretics; Expectorants
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
THE...CITRATE...OF POTASSIUM.../IS/ ADMIN ORALLY. ... 40 MEQ OF POTASSIUM IS PROVIDED BY APPROX...4.3 G OF POTASSIUM CITRATE.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 40:12
A SYSTEMIC & URINARY ALKALIZER & FOR THE EFFECTS OF THE POTASSIUM ION. IT HAS ALSO BEEN USED AS AN EXPECTORANT & A DIURETIC. DOSE- USUAL, 1 G. ...USED IN DOSE OF 1-2 G EVERY FEW HR, DILUTED WITH AT LEAST 1/2 GLASSFUL OF WATER OR FRUIT JUICE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 801
COMPOSITION CONTAINS POTASSIUM CITRATE.
GAGIU F; PREPN FOR TREATMENT OF URIC LITHIASIS; ROMANIAN PATENT NUMBER 57645 09/12/74
MEDICATION (VET): DIURETIC AGENT
The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 990
For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
FDA Label
Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.
Diuretics
Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)
A - Alimentary tract and metabolism
A12 - Mineral supplements
A12B - Potassium
A12BA - Potassium
A12BA02 - Potassium citrate
Route of Elimination
Urinary; less than 5% unchanged.
Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.
After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.
Market Place
